-
2
-
-
34249868241
-
Adoptive T cell therapy for cancer in the clinic
-
June CH Adoptive T cell therapy for cancer in the clinic. J Clin Invest 2007; 117: 1466-76.
-
(2007)
J Clin Invest
, vol.117
, pp. 1466-1476
-
-
June, C.H.1
-
3
-
-
76949100884
-
Accelerated production of antigen-specific T cells for preclinical and clinical applications using gas-permeable rapid expansion cultureware (G-Rex)
-
Vera JF, Brenner LJ, Gerdemann U, Ngo MC, Sili U, Liu H, et al. Accelerated production of antigen-specific T cells for preclinical and clinical applications using gas-permeable rapid expansion cultureware (G-Rex). J Immunother 2010; 33: 305-15.
-
(2010)
J Immunother
, vol.33
, pp. 305-315
-
-
Vera, J.F.1
Brenner, L.J.2
Gerdemann, U.3
Ngo, M.C.4
Sili, U.5
Liu, H.6
-
4
-
-
0024166189
-
Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma: A preliminary report
-
Rosenberg SA, Packard BS, Aebersold PM, Solomon D, Topalian SL, Toy ST, et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma: a preliminary report. N Engl J Med 1988; 319: 1676-80.
-
(1988)
N Engl J Med
, vol.319
, pp. 1676-1680
-
-
Rosenberg, S.A.1
Packard, B.S.2
Aebersold, P.M.3
Solomon, D.4
Topalian, S.L.5
Toy, S.T.6
-
5
-
-
84890239280
-
Adoptive immunotherapy for cancer
-
Ruella M, Kalos M. Adoptive immunotherapy for cancer. Immunol Rev 2014; 257: 14-38.
-
(2014)
Immunol Rev
, vol.257
, pp. 14-38
-
-
Ruella, M.1
Kalos, M.2
-
6
-
-
55949125601
-
Adoptive cell therapy for patients with metastatic melanoma: Evaluation of intensive myeloablative chemoradiation preparative regimens
-
Dudley ME, Yang JC, Sherry R, Hughes MS, Royal R, Kammula U, et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol 2008; 26: 5233-9.
-
(2008)
J Clin Oncol
, vol.26
, pp. 5233-5239
-
-
Dudley, M.E.1
Yang, J.C.2
Sherry, R.3
Hughes, M.S.4
Royal, R.5
Kammula, U.6
-
7
-
-
79960299888
-
Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy
-
Rosenberg SA, Yang JC, Sherry RM, Kammula US, Hughes MS, Phan GQ, et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res 2011; 17: 4550-7.
-
(2011)
Clin Cancer Res
, vol.17
, pp. 4550-4557
-
-
Rosenberg, S.A.1
Yang, J.C.2
Sherry, R.M.3
Kammula, U.S.4
Hughes, M.S.5
Phan, G.Q.6
-
8
-
-
78349255049
-
Transduction of tumor-specific T cells with CXCR2 chemokine receptor improves migration to tumor and antitumor immune responses
-
Peng W, Ye Y, Rabinovich BA, Liu C, Lou Y, Zhang M, et al. Transduction of tumor-specific T cells with CXCR2 chemokine receptor improves migration to tumor and antitumor immune responses. Clin Cancer Res 2010; 16: 5458-68.
-
(2010)
Clin Cancer Res
, vol.16
, pp. 5458-5468
-
-
Peng, W.1
Ye, Y.2
Rabinovich, B.A.3
Liu, C.4
Lou, Y.5
Zhang, M.6
-
9
-
-
35549008976
-
Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer
-
Bollard CM, Gottschalk S, Leen AM, Weiss H, Straathof KC, Carrum G, et al. Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer. Blood 2007; 110: 2838-45.
-
(2007)
Blood
, vol.110
, pp. 2838-2845
-
-
Bollard, C.M.1
Gottschalk, S.2
Leen, A.M.3
Weiss, H.4
Straathof, K.C.5
Carrum, G.6
-
10
-
-
0028816546
-
Use of genemodified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation
-
Rooney CM, Smith CA, Ng CY, Loftin S, Li C, Krance RA, et al. Use of genemodified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet 1995; 345: 9-13.
-
(1995)
Lancet
, vol.345
, pp. 9-13
-
-
Rooney, C.M.1
Smith, C.A.2
Ng, C.Y.3
Loftin, S.4
Li, C.5
Krance, R.A.6
-
11
-
-
20144365643
-
Treatment of nasopharyngeal carcinoma with Epstein-Barr virus-specific T lymphocytes
-
Straathof KC, Bollard CM, Popat U, Huls MH, Lopez T, Morriss MC, et al. Treatment of nasopharyngeal carcinoma with Epstein-Barr virus-specific T lymphocytes. Blood 2005; 105: 1898-904.
-
(2005)
Blood
, vol.105
, pp. 1898-1904
-
-
Straathof, K.C.1
Bollard, C.M.2
Popat, U.3
Huls, M.H.4
Lopez, T.5
Morriss, M.C.6
-
12
-
-
84856845120
-
Generation of polyclonal CMV-specific T cells for the adoptive immunotherapy of glioblastoma
-
Ghazi A, Ashoori A, Hanley PJ, Brawley VS, Shaffer DR, Kew Y, et al. Generation of polyclonal CMV-specific T cells for the adoptive immunotherapy of glioblastoma. J Immunother 2012; 35: 159-68.
-
(2012)
J Immunother
, vol.35
, pp. 159-168
-
-
Ghazi, A.1
Ashoori, A.2
Hanley, P.J.3
Brawley, V.S.4
Shaffer, D.R.5
Kew, Y.6
-
13
-
-
84903621256
-
Autologous T-cell therapy forcytomegalovirus as a consolidative treatment for recurrent glioblastoma
-
Schuessler A, Smith C, Beagley L, Boyle GM, Rehan S, Matthews K, et al. Autologous T-cell therapy forcytomegalovirus as a consolidative treatment for recurrent glioblastoma. Cancer Res 2014; 74: 3466-76.
-
(2014)
Cancer Res
, vol.74
, pp. 3466-3476
-
-
Schuessler, A.1
Smith, C.2
Beagley, L.3
Boyle, G.M.4
Rehan, S.5
Matthews, K.6
-
14
-
-
0037829421
-
Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients
-
Dudley ME, Wunderlich JR, Shelton TE, Even J, Rosenberg SA. Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients. J Immunother 2003; 26: 332-42.
-
(2003)
J Immunother
, vol.26
, pp. 332-342
-
-
Dudley, M.E.1
Wunderlich, J.R.2
Shelton, T.E.3
Even, J.4
Rosenberg, S.A.5
-
16
-
-
84897002504
-
Adoptive immunotherapy for cancer or viruses
-
Maus MV, Fraietta JA, Levine BL, Kalos M, Zhao Y, June CH. Adoptive immunotherapy for cancer or viruses. Annu Rev Immunol 2014; 32: 189-225.
-
(2014)
Annu Rev Immunol
, vol.32
, pp. 189-225
-
-
Maus, M.V.1
Fraietta, J.A.2
Levine, B.L.3
Kalos, M.4
Zhao, Y.5
June, C.H.6
-
17
-
-
33749624177
-
Cancer regression in patients after transfer of genetically engineered lymphocytes
-
Morgan RA, Dudley ME, Wunderlich JR, Hughes MS, Yang JC, Sherry RM, et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 2006; 314: 126-9.
-
(2006)
Science
, vol.314
, pp. 126-129
-
-
Morgan, R.A.1
Dudley, M.E.2
Wunderlich, J.R.3
Hughes, M.S.4
Yang, J.C.5
Sherry, R.M.6
-
18
-
-
79952304769
-
Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NYESO-1
-
Robbins PF, Morgan RA, Feldman SA, Yang JC, Sherry RM, Dudley ME, et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NYESO-1. J Clin Oncol 2011; 29: 917-24.
-
(2011)
J Clin Oncol
, vol.29
, pp. 917-924
-
-
Robbins, P.F.1
Morgan, R.A.2
Feldman, S.A.3
Yang, J.C.4
Sherry, R.M.5
Dudley, M.E.6
-
19
-
-
33845985925
-
Efficiency of T-cell receptor expression in dual-specific T cells is controlled by the intrinsic qualities of the TCR chains within the TCR-CD3 complex
-
Heemskerk MH, Hagedoorn RS, van der Hoorn MA, van der Veken LT, Hoogeboom M, Kester MG, et al. Efficiency of T-cell receptor expression in dual-specific T cells is controlled by the intrinsic qualities of the TCR chains within the TCR-CD3 complex. Blood 2007; 109: 235-43.
-
(2007)
Blood
, vol.109
, pp. 235-243
-
-
Heemskerk, M.H.1
Hagedoorn, R.S.2
Van Der Hoorn, M.A.3
Van Der Veken, L.T.4
Hoogeboom, M.5
Kester, M.G.6
-
20
-
-
84920390437
-
Survivin-specific T cell receptor targets tumor but not T cells
-
Arber C, Feng X, Abhyankar H, Romero E, Wu MF, Heslop HE, et al. Survivin-specific T cell receptor targets tumor but not T cells. J Clin Invest 2015; 125: 157-68.
-
(2015)
J Clin Invest
, vol.125
, pp. 157-168
-
-
Arber, C.1
Feng, X.2
Abhyankar, H.3
Romero, E.4
Wu, M.F.5
Heslop, H.E.6
-
21
-
-
33947217494
-
Facilitating matched pairing and expression of TCR chains introduced into human T cells
-
Kuball J, Dossett ML, Wolfl M, Ho WY, Voss RH, Fowler C, et al. Facilitating matched pairing and expression of TCR chains introduced into human T cells. Blood 2007; 109: 2331-8.
-
(2007)
Blood
, vol.109
, pp. 2331-2338
-
-
Kuball, J.1
Dossett, M.L.2
Wolfl, M.3
Ho, W.Y.4
Voss, R.H.5
Fowler, C.6
-
22
-
-
47249100641
-
Human TCR that incorporate CD3z induce highly preferred pairing between TCRα and β chains following gene transfer
-
Sebestyen Z, Schooten E, Sals T, Zaldivar I, San Jose E, Alarcon B, et al. Human TCR that incorporate CD3z induce highly preferred pairing between TCRα and β chains following gene transfer. J Immunol 2008; 180: 7736-46.
-
(2008)
J Immunol
, vol.180
, pp. 7736-7746
-
-
Sebestyen, Z.1
Schooten, E.2
Sals, T.3
Zaldivar, I.4
San Jose, E.5
Alarcon, B.6
-
23
-
-
33645517072
-
αβT-cell receptor engineered gd T cells mediate effective antileukemic reactivity
-
van der Veken LT, Hagedoorn RS, van Loenen MM, Willemze R, Falkenburg JH, Heemskerk MH. αβT-cell receptor engineered gd T cells mediate effective antileukemic reactivity. Cancer Res 2006; 66: 3331-7.
-
(2006)
Cancer Res
, vol.66
, pp. 3331-3337
-
-
Van Der Veken, L.T.1
Hagedoorn, R.S.2
Van Loenen, M.M.3
Willemze, R.4
Falkenburg, J.H.5
Heemskerk, M.H.6
-
24
-
-
84891076242
-
Immunotherapy with TCR-redirected Tcells: Comparison of TCR-transduced and TCR-engineered hematopoietic stem cell-derived T cells
-
Starck L, Popp K, Pircher H, Uckert W. Immunotherapy with TCR-redirected Tcells: comparison of TCR-transduced and TCR-engineered hematopoietic stem cell-derived T cells. J Immunol 2014; 192: 206-13.
-
(2014)
J Immunol
, vol.192
, pp. 206-213
-
-
Starck, L.1
Popp, K.2
Pircher, H.3
Uckert, W.4
-
25
-
-
84860681545
-
Editing T cell specificity towards leukemia by zinc finger nucleases and lentiviral gene transfer
-
Provasi E, Genovese P, Lombardo A, Magnani Z, Liu PQ, Reik A, et al. Editing T cell specificity towards leukemia by zinc finger nucleases and lentiviral gene transfer. Nat Med 2012; 18: 807-15.
-
(2012)
Nat Med
, vol.18
, pp. 807-815
-
-
Provasi, E.1
Genovese, P.2
Lombardo, A.3
Magnani, Z.4
Liu, P.Q.5
Reik, A.6
-
26
-
-
0027471898
-
Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors
-
Eshhar Z, Waks T, Gross G, Schindler DG. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci U S A 1993; 90: 720-4.
-
(1993)
Proc Natl Acad Sci USA
, vol.90
, pp. 720-724
-
-
Eshhar, Z.1
Waks, T.2
Gross, G.3
Schindler, D.G.4
-
27
-
-
84890181067
-
Design and development of therapies using chimeric antigen receptor-expressing T cells
-
Dotti G, Gottschalk S, Savoldo B, Brenner MK. Design and development of therapies using chimeric antigen receptor-expressing T cells. Immunol Rev 2014; 257: 107-26.
-
(2014)
Immunol Rev
, vol.257
, pp. 107-126
-
-
Dotti, G.1
Gottschalk, S.2
Savoldo, B.3
Brenner, M.K.4
-
28
-
-
84899631361
-
Antibody-modified T cells: CARs take the front seat for hematologic malignancies
-
Maus MV, Grupp SA, Porter DL, June CH. Antibody-modified T cells: CARs take the front seat for hematologic malignancies. Blood 2014; 123: 2625-35.
-
(2014)
Blood
, vol.123
, pp. 2625-2635
-
-
Maus, M.V.1
Grupp, S.A.2
Porter, D.L.3
June, C.H.4
-
29
-
-
79955517235
-
CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients
-
Savoldo B, Ramos CA, Liu E, Mims MP, Keating MJ, Carrum G, et al. CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J Clin Invest 2011; 121: 1822-6.
-
(2011)
J Clin Invest
, vol.121
, pp. 1822-1826
-
-
Savoldo, B.1
Ramos, C.A.2
Liu, E.3
Mims, M.P.4
Keating, M.J.5
Carrum, G.6
-
30
-
-
84912138759
-
Bispecific antibody platforms for cancer immunotherapy
-
Lameris R, de Bruin RC, Schneiders FL, van Bergen En Henegouwen PM, Verheul HM, de Gruijl TD, et al. Bispecific antibody platforms for cancer immunotherapy. Crit Rev Oncol Hematol 2014; 92: 153-65.
-
(2014)
Crit Rev Oncol Hematol
, vol.92
, pp. 153-165
-
-
Lameris, R.1
De Bruin, R.C.2
Schneiders, F.L.3
Van Bergen En Henegouwen, P.M.4
Verheul, H.M.5
De Gruijl, T.D.6
-
31
-
-
84920691639
-
Engager T cells: A new class of antigen-specific T cells that redirect bystander T cells
-
Iwahori K, Kakarla S, Velasquez MP, Yu F, Yi Z, Gerken C, et al. Engager T cells: a new class of antigen-specific T cells that redirect bystander T cells. Mol Ther 2015; 23: 171-8.
-
(2015)
Mol Ther
, vol.23
, pp. 171-178
-
-
Iwahori, K.1
Kakarla, S.2
Velasquez, M.P.3
Yu, F.4
Yi, Z.5
Gerken, C.6
-
32
-
-
84887471195
-
Combinational targeting offsets antigen escape and enhances effector functions of adoptively transferred T cells in glioblastoma
-
Hegde M, Corder A, Chow KK, Mukherjee M, Ashoori A, Kew Y, et al. Combinational targeting offsets antigen escape and enhances effector functions of adoptively transferred T cells in glioblastoma. Mol Ther 2013; 21: 2087-101.
-
(2013)
Mol Ther
, vol.21
, pp. 2087-2101
-
-
Hegde, M.1
Corder, A.2
Chow, K.K.3
Mukherjee, M.4
Ashoori, A.5
Kew, Y.6
-
33
-
-
84880259439
-
TanCAR: A novel bispecific chimeric antigen receptor for cancer immunotherapy
-
Grada Z, Hegde M, Byrd T, Shaffer DR, Ghazi A, Brawley VS, et al. TanCAR: a novel bispecific chimeric antigen receptor for cancer immunotherapy. Mol Ther Nucleic Acids 2013; 2: e105.
-
(2013)
Mol Ther Nucleic Acids
, vol.2
, pp. e105
-
-
Grada, Z.1
Hegde, M.2
Byrd, T.3
Shaffer, D.R.4
Ghazi, A.5
Brawley, V.S.6
-
34
-
-
84881312673
-
Antitumor effects of chimeric receptor engineered human T cells directed to tumor stroma
-
Kakarla S, Chow KK, Mata M, Shaffer DR, Song XT, Wu MF, et al. Antitumor effects of chimeric receptor engineered human T cells directed to tumor stroma. Mol Ther 2013; 21: 1611-20.
-
(2013)
Mol Ther
, vol.21
, pp. 1611-1620
-
-
Kakarla, S.1
Chow, K.K.2
Mata, M.3
Shaffer, D.R.4
Song, X.T.5
Wu, M.F.6
-
35
-
-
55249117972
-
Antitumor activity of EBV-specific T lymphocytes transduced with a dominant negative TGF-b receptor
-
Foster AE, Dotti G, Lu A, Khalil M, Brenner MK, Heslop HE, et al. Antitumor activity of EBV-specific T lymphocytes transduced with a dominant negative TGF-b receptor. J Immunother 2008; 31: 500-5.
-
(2008)
J Immunother
, vol.31
, pp. 500-505
-
-
Foster, A.E.1
Dotti, G.2
Lu, A.3
Khalil, M.4
Brenner, M.K.5
Heslop, H.E.6
-
36
-
-
84902146901
-
Reversal of tumor immune inhibition using a chimeric cytokine receptor
-
Leen AM, Sukumaran S, Watanabe N, Mohammed S, Keirnan J, Yanagisawa R, et al. Reversal of tumor immune inhibition using a chimeric cytokine receptor. Mol Ther 2014; 22: 1211-20.
-
(2014)
Mol Ther
, vol.22
, pp. 1211-1220
-
-
Leen, A.M.1
Sukumaran, S.2
Watanabe, N.3
Mohammed, S.4
Keirnan, J.5
Yanagisawa, R.6
-
37
-
-
19944426039
-
New frontiers in translational research in neuro-oncology and the blood-brain barrier: Report of the tenth annual Blood-Brain Barrier Disruption Consortium Meeting
-
Doolittle ND, Abrey LE, Bleyer WA, Brem S, Davis TP, Dore-Duffy P, et al. New frontiers in translational research in neuro-oncology and the blood-brain barrier: report of the tenth annual Blood-Brain Barrier Disruption Consortium Meeting. Clin Cancer Res 2005; 11: 421-8.
-
(2005)
Clin Cancer Res
, vol.11
, pp. 421-428
-
-
Doolittle, N.D.1
Abrey, L.E.2
Bleyer, W.A.3
Brem, S.4
Davis, T.P.5
Dore-Duffy, P.6
-
39
-
-
84858766182
-
The blockade of immune checkpoints in cancer immunotherapy
-
Pardoll DM The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012; 12: 252-64.
-
(2012)
Nat Rev Cancer
, vol.12
, pp. 252-264
-
-
Pardoll, D.M.1
-
40
-
-
77954801079
-
Improved survival with ipilimumab in patients with metastatic melanoma
-
Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363: 711-23.
-
(2010)
N Engl J Med
, vol.363
, pp. 711-723
-
-
Hodi, F.S.1
O'Day, S.J.2
McDermott, D.F.3
Weber, R.W.4
Sosman, J.A.5
Haanen, J.B.6
-
41
-
-
84862859820
-
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer
-
Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366: 2443-54.
-
(2012)
N Engl J Med
, vol.366
, pp. 2443-2454
-
-
Topalian, S.L.1
Hodi, F.S.2
Brahmer, J.R.3
Gettinger, S.N.4
Smith, D.C.5
McDermott, D.F.6
-
42
-
-
84862903106
-
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
-
Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012; 366: 2455-65.
-
(2012)
N Engl J Med
, vol.366
, pp. 2455-2465
-
-
Brahmer, J.R.1
Tykodi, S.S.2
Chow, L.Q.3
Hwu, W.J.4
Topalian, S.L.5
Hwu, P.6
-
43
-
-
70149114880
-
Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen
-
Johnson LA, Morgan RA, Dudley ME, Cassard L, Yang JC, Hughes MS, et al. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood 2009; 114: 535-46.
-
(2009)
Blood
, vol.114
, pp. 535-546
-
-
Johnson, L.A.1
Morgan, R.A.2
Dudley, M.E.3
Cassard, L.4
Yang, J.C.5
Hughes, M.S.6
-
44
-
-
84880730689
-
Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma
-
Linette GP, Stadtmauer EA, Maus MV, Rapoport AP, Levine BL, Emery L, et al. Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. Blood 2013; 122: 863-71.
-
(2013)
Blood
, vol.122
, pp. 863-871
-
-
Linette, G.P.1
Stadtmauer, E.A.2
Maus, M.V.3
Rapoport, A.P.4
Levine, B.L.5
Emery, L.6
-
45
-
-
77950475517
-
Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2
-
Morgan RA, Yang JC, Kitano M, Dudley ME, Laurencot CM, Rosenberg SA. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther 2010; 18: 843-51.
-
(2010)
Mol Ther
, vol.18
, pp. 843-851
-
-
Morgan, R.A.1
Yang, J.C.2
Kitano, M.3
Dudley, M.E.4
Laurencot, C.M.5
Rosenberg, S.A.6
-
46
-
-
84890207337
-
T cells expressing chimeric antigen receptors can cause anaphylaxis in humans
-
Maus MV, Haas AR, Beatty GL, Albelda SM, Levine BL, Liu X, et al. T cells expressing chimeric antigen receptors can cause anaphylaxis in humans. Cancer Immunol Res 2013; 1: 26-31.
-
(2013)
Cancer Immunol Res
, vol.1
, pp. 26-31
-
-
Maus, M.V.1
Haas, A.R.2
Beatty, G.L.3
Albelda, S.M.4
Levine, B.L.5
Liu, X.6
-
47
-
-
65349157330
-
Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): A non-randomised phase I-II study
-
Ciceri F, Bonini C, Stanghellini MT, Bondanza A, Traversari C, Salomoni M, et al. Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase I-II study. Lancet Oncol 2009; 10: 489-500.
-
(2009)
Lancet Oncol
, vol.10
, pp. 489-500
-
-
Ciceri, F.1
Bonini, C.2
Stanghellini, M.T.3
Bondanza, A.4
Traversari, C.5
Salomoni, M.6
-
48
-
-
80455162464
-
Inducible apoptosis as a safety switch for adoptive cell therapy
-
Di Stasi A, Tey SK, Dotti G, Fujita Y, Kennedy-Nasser A, Martinez C, et al. Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med 2011; 365: 1673-83.
-
(2011)
N Engl J Med
, vol.365
, pp. 1673-1683
-
-
Di Stasi, A.1
Tey, S.K.2
Dotti, G.3
Fujita, Y.4
Kennedy-Nasser, A.5
Martinez, C.6
-
49
-
-
84872196489
-
Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells
-
Kloss CC, Condomines M, Cartellieri M, Bachmann M, Sadelain M. Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells. Nat Biotechnol 2013; 31: 71-5.
-
(2013)
Nat Biotechnol
, vol.31
, pp. 71-75
-
-
Kloss, C.C.1
Condomines, M.2
Cartellieri, M.3
Bachmann, M.4
Sadelain, M.5
-
50
-
-
84904097189
-
Current concepts in the diagnosis and management of cytokine release syndrome
-
Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood 2014; 124: 188-95.
-
(2014)
Blood
, vol.124
, pp. 188-195
-
-
Lee, D.W.1
Gardner, R.2
Porter, D.L.3
Louis, C.U.4
Ahmed, N.5
Jensen, M.6
-
51
-
-
0029688251
-
Adoptive cellular immunotherapy of cancer in mice using allogeneic T-cells
-
Bartels CJ, Rosenberg SA, Yang JC. Adoptive cellular immunotherapy of cancer in mice using allogeneic T-cells. Ann Surg Oncol 1996; 3: 67-73.
-
(1996)
Ann Surg Oncol
, vol.3
, pp. 67-73
-
-
Bartels, C.J.1
Rosenberg, S.A.2
Yang, J.C.3
-
52
-
-
34250844475
-
Regression of experimental medulloblastoma following transfer of HER2specific T cells
-
Ahmed N, Ratnayake M, Savoldo B, Perlaky L, Dotti G, Wels WS, et al. Regression of experimental medulloblastoma following transfer of HER2specific T cells. Cancer Res 2007; 67: 5957-64.
-
(2007)
Cancer Res
, vol.67
, pp. 5957-5964
-
-
Ahmed, N.1
Ratnayake, M.2
Savoldo, B.3
Perlaky, L.4
Dotti, G.5
Wels, W.S.6
-
53
-
-
74549196076
-
HER2specific T cells target primary glioblastoma stem cells and induce regression of autologous experimental tumors
-
Ahmed N, Salsman VS, Kew Y, Shaffer D, Powell S, Zhang YJ, et al. HER2specific T cells target primary glioblastoma stem cells and induce regression of autologous experimental tumors. Clin Cancer Res 2010; 16: 474-85.
-
(2010)
Clin Cancer Res
, vol.16
, pp. 474-485
-
-
Ahmed, N.1
Salsman, V.S.2
Kew, Y.3
Shaffer, D.4
Powell, S.5
Zhang, Y.J.6
-
54
-
-
70349852616
-
Immunotherapy for osteosarcoma: Genetic modification of T cells overcomes low levels of tumor antigen expression
-
Ahmed N, Salsman VS, Yvon E, Louis CU, Perlaky L, Wels WS, et al. Immunotherapy for osteosarcoma: genetic modification of T cells overcomes low levels of tumor antigen expression. Mol Ther 2009; 17: 1779-87.
-
(2009)
Mol Ther
, vol.17
, pp. 1779-1787
-
-
Ahmed, N.1
Salsman, V.S.2
Yvon, E.3
Louis, C.U.4
Perlaky, L.5
Wels, W.S.6
-
55
-
-
84859820456
-
Stem-like tumor-initiating cells isolated from IL13Ra2 expressing gliomas are targeted and killed by IL13-zetakine-redirected T Cells
-
Brown CE, Starr R, Aguilar B, Shami AF, Martinez C, D'Apuzzo M, et al. Stem-like tumor-initiating cells isolated from IL13Ra2 expressing gliomas are targeted and killed by IL13-zetakine-redirected T Cells. Clin Cancer Res 2012; 18: 2199-209.
-
(2012)
Clin Cancer Res
, vol.18
, pp. 2199-2209
-
-
Brown, C.E.1
Starr, R.2
Aguilar, B.3
Shami, A.F.4
Martinez, C.5
D'Apuzzo, M.6
-
56
-
-
84875215925
-
T cells redirected to EphA2 for the immunotherapy of glioblastoma
-
Chow KK, Naik S, Kakarla S, Brawley VS, Shaffer DR, Yi Z, et al. T cells redirected to EphA2 for the immunotherapy of glioblastoma. Mol Ther 2013; 21: 629-37.
-
(2013)
Mol Ther
, vol.21
, pp. 629-637
-
-
Chow, K.K.1
Naik, S.2
Kakarla, S.3
Brawley, V.S.4
Shaffer, D.R.5
Yi, Z.6
-
57
-
-
84911213409
-
Genetic modification of T cells with a novel bispecific chimeric antigen receptor to enhance the control of high-grade glioma (HGG)
-
10027
-
Hegde M, Wakefield A, Brawley VS, Grada Z, Byrd TT, Chow KK, et al. Genetic modification of T cells with a novel bispecific chimeric antigen receptor to enhance the control of high-grade glioma (HGG). J Clin Oncol 32: 15s, 2014. (suppl; abstr 10027).
-
(2014)
J Clin Oncol
, vol.32
, pp. 15s
-
-
Hegde, M.1
Wakefield, A.2
Brawley, V.S.3
Grada, Z.4
Byrd, T.T.5
Chow, K.K.6
-
58
-
-
79952187823
-
T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis
-
Parkhurst MR, Yang JC, Langan RC, Dudley ME, Nathan DA, Feldman SA, et al. T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Mol Ther 2011; 19: 620-6.
-
(2011)
Mol Ther
, vol.19
, pp. 620-626
-
-
Parkhurst, M.R.1
Yang, J.C.2
Langan, R.C.3
Dudley, M.E.4
Nathan, D.A.5
Feldman, S.A.6
-
59
-
-
84933513655
-
Human epidermal growth factor receptor 2 (HER2) -specific chimeric antigen receptor-modified T cells for the immunotherapy of HER2-positive sarcoma
-
Ahmed N, Brawley VS, Hegde M, Robertson C, Ghazi A, Gerken C, et al. Human epidermal growth factor receptor 2 (HER2) -specific chimeric antigen receptor-modified T cells for the immunotherapy of HER2-positive sarcoma. J Clin Oncol 2015; 33: 1688-96.
-
(2015)
J Clin Oncol
, vol.33
, pp. 1688-1696
-
-
Ahmed, N.1
Brawley, V.S.2
Hegde, M.3
Robertson, C.4
Ghazi, A.5
Gerken, C.6
-
60
-
-
82955207691
-
Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma
-
Louis CU, Savoldo B, Dotti G, Pule M, Yvon E, Myers GD, et al. Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. Blood 2011; 118: 6050-6.
-
(2011)
Blood
, vol.118
, pp. 6050-6056
-
-
Louis, C.U.1
Savoldo, B.2
Dotti, G.3
Pule, M.4
Yvon, E.5
Myers, G.D.6
-
61
-
-
55549145071
-
Virusspecific Tcells engineered to coexpress tumor-specific receptors: Persistence and antitumor activity in individuals with neuroblastoma
-
Pule MA, Savoldo B, Myers GD, Rossig C, Russell HV, Dotti G, et al. Virusspecific Tcells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med 2008; 14: 1264-70.
-
(2008)
Nat Med
, vol.14
, pp. 1264-1270
-
-
Pule, M.A.1
Savoldo, B.2
Myers, G.D.3
Rossig, C.4
Russell, H.V.5
Dotti, G.6
|